Trends in Time Spent Viremic Among Persons Newly Diagnosed With HIV in San Francisco.
Journal
Journal of acquired immune deficiency syndromes (1999)
ISSN: 1944-7884
Titre abrégé: J Acquir Immune Defic Syndr
Pays: United States
ID NLM: 100892005
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
received:
08
12
2022
accepted:
18
05
2023
medline:
15
9
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
ppublish
Résumé
To examine trends in time spent viremic and initiation into antiretroviral treatment (ART) among persons newly diagnosed with HIV in San Francisco. Using HIV surveillance data, we included persons diagnosed with HIV during 2012-2020, a San Francisco resident at HIV diagnosis, alive 12 months after HIV diagnosis, and had ≥2 viral load tests within 12 months after diagnosis. Percent person-time spent (pPT) >200, pPT >1500, and pPT >10,000 copies per milliliter was calculated during the 12 months after HIV diagnosis. Multivariate regression models assessed the year of diagnosis and time spent above each viral threshold and year of diagnosis and ART initiation within 0-7 days (rapid), 8-365 days (delayed), or no ART initiation. Of 2471 new HIV diagnoses in San Francisco from 2012 to 2020, 1921 (72%) were included. Newly diagnosed persons spent a mean of 40.4% pPT >200, 32.4% pPT >1,500%, and 23.4% pPT >10,000 copies per milliliter; 33.8% had rapid ART initiation, 57.3% delayed, and 9% had no ART initiation. After adjustment, persons diagnosed in years 2014-2015, 2016-2017, 2018-2019, and 2020 were associated with less time spent above all viral thresholds and lower risk of delayed or no ART initiation compared with those diagnosed in 2012-2013. Greater time above thresholds correlated with injection drug use, ages 25-29 and 30-39 years, and homelessness. Percent time spent above each viremic level decreased significantly, whereas rapid ART initiation increased among newly diagnosed persons from 2014 through 2020 compared with 2012-2013. Population differences in time spent unsuppressed highlight the need for targeted interventions to reduce new HIV infections and improve health.
Identifiants
pubmed: 37707298
doi: 10.1097/QAI.0000000000003237
pii: 00126334-202310010-00003
pmc: PMC10497196
mid: NIHMS1908361
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Research Support, U.S. Gov't, P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
107-115Subventions
Organisme : Intramural CDC HHS
ID : NU62PS924536
Pays : United States
Organisme : NCHHSTP CDC HHS
ID : NU62PS924536
Pays : United States
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
AIDS Care. 2011 Mar;23(3):383-92
pubmed: 21347902
Am J Public Health. 2016 Jan;106(1):e1-e23
pubmed: 26562123
AIDS Behav. 2021 Jan;25(1):249-258
pubmed: 32643021
AIDS. 2018 Sep 10;32(14):2033-2042
pubmed: 29958190
JAMA. 2023 Jan 3;329(1):52-62
pubmed: 36594946
AIDS. 2019 Apr 1;33(5):825-832
pubmed: 30882490
BMJ. 2010 May 14;340:c2205
pubmed: 20472675
AIDS Behav. 2018 Nov;22(11):3443-3450
pubmed: 29541913
J Acquir Immune Defic Syndr. 2002 Mar 1;29(3):275-83
pubmed: 11873077
AIDS. 2018 May 15;32(8):1059-1067
pubmed: 29424782
N Engl J Med. 2000 Mar 30;342(13):921-9
pubmed: 10738050
Open Forum Infect Dis. 2021 Jun 22;8(7):ofab330
pubmed: 34307729
BMC Public Health. 2009 Jan 14;9:17
pubmed: 19144168
AIDS Behav. 2022 Nov;26(11):3480-3493
pubmed: 35445996
AIDS. 2009 Jul 17;23(11):1397-404
pubmed: 19381076
Clin Infect Dis. 2021 Jul 1;73(1):e122-e128
pubmed: 32449916
Am J Prev Med. 2021 Nov;61(5 Suppl 1):S47-S54
pubmed: 34686290
J Acquir Immune Defic Syndr. 2015 Apr 1;68(4):413-9
pubmed: 25559604
Clin Infect Dis. 2016 Oct 1;63(7):976-83
pubmed: 27358354
Lancet. 2010 Jun 12;375(9731):2092-8
pubmed: 20537376
PLoS One. 2014 Feb 12;9(2):e87872
pubmed: 24533061
AIDS. 2018 Aug 24;32(13):1881-1889
pubmed: 29894384
J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):205-12
pubmed: 27105049
J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):579-84
pubmed: 27070123
J Acquir Immune Defic Syndr. 2003 Feb;32 Suppl 1:S68-85
pubmed: 12571518
N Engl J Med. 2011 Aug 11;365(6):493-505
pubmed: 21767103
MMWR Morb Mortal Wkly Rep. 2020 Oct 09;69(40):1437-1442
pubmed: 33031362